Global seroprevalence of SARS-CoV-2 antibodies¶
Bobrovitz, N., & Arora. (2021). Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Outbreak Underascertainment
- The COVID-19 pandemic provided a large-scale demonstration: pooling 968 seroprevalence studies from 74 countries, Bobrovitz and colleagues found that national seroprevalence estimates implied a median of 18.1 times more infections than the corresponding cumulative reported cases (interquartile range 5.9–38.7), with the ratio varying between regions from 6.7 in South Asia to 602.5 in sub-Saharan Africa
This sourceBobrovitz et al.'s meta-analysis of 968 serosurveys across 74 countries is the large-scale demonstration the sentence describes: national seroprevalence estimates ran a median 18.1 times higher than the corresponding cumulative reported cases (IQR 5.9-38.7), with variation between regions from 6.7 in South Asia to 602.5 in sub-Saharan Africa.
- The COVID-19 pandemic provided a large-scale demonstration: pooling 968 seroprevalence studies from 74 countries, Bobrovitz and colleagues found that national seroprevalence estimates implied a median of 18.1 times more infections than the corresponding cumulative reported cases (interquartile range 5.9–38.7), with the ratio varying between regions from 6.7 in South Asia to 602.5 in sub-Saharan Africa
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:d81adc91dc30 · see in the full table